<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720430</url>
  </required_header>
  <id_info>
    <org_study_id>19D.737</org_study_id>
    <nct_id>NCT04720430</nct_id>
  </id_info>
  <brief_title>Blood Sample Collection for Experimental Blood Test to Track Liver Cancer</brief_title>
  <official_title>Circulating MicroRNA Levels as a Predictor of Successful Bridging or Down-Staging Loco-Regional Therapy (LRT) to Liver Transplantation for Patients With Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates if an experimental blood test can help predict how well cancer will&#xD;
      remain under control with treatment. Ther experimental blood test involves measuring&#xD;
      mircoRNAs. MicroRNAs are small molecules which help regulate how genes are expressed. This&#xD;
      information may help researchers guide treatment for other patients in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Clinical Status - Liver Transplant</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>Undergoing liver transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Clinical Status - Death</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>Will assess the following: death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Clinical Status - Candidacy</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>No longer candidate for transplantation for reasons other than tumor progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Clinical Status</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>No longer candidate for transplantation due to tumor progression despite loco-regional therapy efforts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of &quot;Wait List Drop Off&quot;</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>Will be estimated and presented with a Clopper-Pearson exact binomial confidence interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to &quot;Wait List Drop Off&quot;</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Cox proportinal hazards modeling will be used to investigate the associations of each micro ribonucleic acid (miRNO) with time to &quot;wait list drop off&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status of the subset of patients successfully reaching liver transplant</measure>
    <time_frame>At 1 year after transplantation</time_frame>
    <description>Logistic regression modeling will be used to investigate the correlation of each miRNA with clincial status (alive without recurrence vs. recurrence or death) within one year of transplant will be cinducted in the subset of those undergoing transplant. The p-values will be adjusted for false discovery rate inflation by the methods of Benjamni &amp; Hochberg (1995) for both secondary analyses, respectively</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patientss with hepatocellular carcinoma felt to be reasonable candidate for liver&#xD;
        transplantation, potentially contingent on success of down-staging therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed and dated informed consent form&#xD;
&#xD;
          -  Willing to comply with all study procedures and be available for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Definite diagnosis of hepatocellular carcinoma established (by standard radiographic&#xD;
             or histologic criteria)&#xD;
&#xD;
          -  Felt to be reasonable candidate for liver transplantation, potentially contingent on&#xD;
             success of down-staging therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Either active or recent solid organ cancer other than hepatocellur carcinoma (HCC)&#xD;
             within the last 5 years, unless determined by transplant hepatology team not to&#xD;
             represent contra-indication to liver transplantation&#xD;
&#xD;
          -  Contra-indication to LRT (as assessed by interventional radiologist, for example&#xD;
             severe thrombocytopenia, severe vascular disease precluding access, etc)&#xD;
&#xD;
          -  History of prior liver transplantation&#xD;
&#xD;
          -  Active or prior systemic therapy for HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jesse Civan, MD</last_name>
    <phone>215-955-8900</phone>
    <email>Jesse.Civan@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Civan</last_name>
      <phone>215-955-8900</phone>
      <email>Jesse.Civan@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

